中国药业
中國藥業
중국약업
China Pharmaceuticals
2015年
17期
39-40
,共2页
王明慧%杨涛%方春燕%梁萍
王明慧%楊濤%方春燕%樑萍
왕명혜%양도%방춘연%량평
特发性血小板减少性紫癜%血小板输注%免疫调节
特髮性血小闆減少性紫癜%血小闆輸註%免疫調節
특발성혈소판감소성자전%혈소판수주%면역조절
idioPathic thrombocytoPenic PurPura%Platelet transfusion%immune regulation
目的：观察人免疫球蛋白联合血小板输注对特发性血小板减少性紫癜的免疫调节作用。方法选择2010年1月至2013年10月收治的患者40例，随机分为对照组与观察组，每组20例。两组均给予常规治疗，观察组在常规治疗基础上，在输注血小板1个治疗剂量前予静脉滴注丙种球蛋白0.4 g/kg，次日和第3日再次予静脉滴注丙种球蛋白0.4 g/(kg·d)。结果观察组治疗1个疗程后，显效率为65.00％，总有效率为100.00％，显著高于对照组的25.00％和65.00％（ P＜0.05）；观察组治疗后24 h血小板计数优于对照组（ P＜0.05）；观察组CCI 24≥4.5×109/L的比例高于对照组（ P＜0.05）；观察组止血时间、血小板数量达正常时间、血小板数量达峰值时间和峰值与对照组比较，差异有统计学意义（ P＜0.05）；观察组治疗后CD3＋，CD4＋，CD8＋，CD4＋/CD8＋水平优于对照组（ P＜0.05）；两组治疗后血小板相关抗体（PAIgG）均下降，且观察组降幅大于对照组（ P＜0.05）；观察组治疗后白细胞介素－4（IL－4）为（61.19±10.42）ng/L，对照组为（72.12±11.39）ng/L，两组比较差异有统计学意义（ t＝4.068，P＜0.05）。结论人免疫球蛋白联合血小板输注能调节特发性血小板减少性紫癜患者机体的免疫功能，改善预后。
目的：觀察人免疫毬蛋白聯閤血小闆輸註對特髮性血小闆減少性紫癜的免疫調節作用。方法選擇2010年1月至2013年10月收治的患者40例，隨機分為對照組與觀察組，每組20例。兩組均給予常規治療，觀察組在常規治療基礎上，在輸註血小闆1箇治療劑量前予靜脈滴註丙種毬蛋白0.4 g/kg，次日和第3日再次予靜脈滴註丙種毬蛋白0.4 g/(kg·d)。結果觀察組治療1箇療程後，顯效率為65.00％，總有效率為100.00％，顯著高于對照組的25.00％和65.00％（ P＜0.05）；觀察組治療後24 h血小闆計數優于對照組（ P＜0.05）；觀察組CCI 24≥4.5×109/L的比例高于對照組（ P＜0.05）；觀察組止血時間、血小闆數量達正常時間、血小闆數量達峰值時間和峰值與對照組比較，差異有統計學意義（ P＜0.05）；觀察組治療後CD3＋，CD4＋，CD8＋，CD4＋/CD8＋水平優于對照組（ P＜0.05）；兩組治療後血小闆相關抗體（PAIgG）均下降，且觀察組降幅大于對照組（ P＜0.05）；觀察組治療後白細胞介素－4（IL－4）為（61.19±10.42）ng/L，對照組為（72.12±11.39）ng/L，兩組比較差異有統計學意義（ t＝4.068，P＜0.05）。結論人免疫毬蛋白聯閤血小闆輸註能調節特髮性血小闆減少性紫癜患者機體的免疫功能，改善預後。
목적：관찰인면역구단백연합혈소판수주대특발성혈소판감소성자전적면역조절작용。방법선택2010년1월지2013년10월수치적환자40례，수궤분위대조조여관찰조，매조20례。량조균급여상규치료，관찰조재상규치료기출상，재수주혈소판1개치료제량전여정맥적주병충구단백0.4 g/kg，차일화제3일재차여정맥적주병충구단백0.4 g/(kg·d)。결과관찰조치료1개료정후，현효솔위65.00％，총유효솔위100.00％，현저고우대조조적25.00％화65.00％（ P＜0.05）；관찰조치료후24 h혈소판계수우우대조조（ P＜0.05）；관찰조CCI 24≥4.5×109/L적비례고우대조조（ P＜0.05）；관찰조지혈시간、혈소판수량체정상시간、혈소판수량체봉치시간화봉치여대조조비교，차이유통계학의의（ P＜0.05）；관찰조치료후CD3＋，CD4＋，CD8＋，CD4＋/CD8＋수평우우대조조（ P＜0.05）；량조치료후혈소판상관항체（PAIgG）균하강，차관찰조강폭대우대조조（ P＜0.05）；관찰조치료후백세포개소－4（IL－4）위（61.19±10.42）ng/L，대조조위（72.12±11.39）ng/L，량조비교차이유통계학의의（ t＝4.068，P＜0.05）。결론인면역구단백연합혈소판수주능조절특발성혈소판감소성자전환자궤체적면역공능，개선예후。
Objective To investigate the immune regulation effect of Platelet transfusion for idioPathic thrombocytoPenia PurPura. Methods 40 cases of children from January 2010 to October 2013 were selected and randomly divided into the control grouP and the observation grouP, 20 cases in each grouP. The two grouPs were given conventional treatment;on the basis of conventional theraPy, the observation grouP were given the Platelet transfusion 1 dose of theraPy with intravenous gamma globulin 0. 4 g/kg, and on the next day and the 3rd day received intravenous immunoglobulin 0. 4 g/ ( kg·d ) . Results After 1 course of treatment, the obvious effective rate of the ob-servation grouP was 65. 00%, and the total effective rate was 100. 00%, which were significantly higher than 25. 00% and 65. 00% of the control grouP ( P < 0. 05 );after 24 h of treatment, the Platelet count ( × 109/L ) of the observation grouP was better than that of the control grouP ( P < 0. 05 );CCI 24 ≥ 4. 5 × 109/L of the observation grouP was better than that of the control grouP ( P < 0. 05 );comPared with the control grouP, the time of hemostasis, Platelet count reaching normal, Platelet count reaching the Peak, and the Peak value of the observation grouP showed statistical differences ( P < 0. 05 );after treatment, the CD3 +, CD4 +, CD8 +, CD4 + /CD8 + of the ob-servation grouP were better than those of the control grouP ( P < 0. 05 ); the Platelet associated antibody ( PAIgG ) of the two grouPs after treatment had statistical difference comPared with before treatment ( P < 0. 05 );after treatment, the IL-4 of the observation grouP was ( 61. 19 ± 10. 42 ) ng/mL, which was lower than ( 72. 12 ± 11. 39 ) ng/mL of the control grouP ( t=4. 068, P < 0. 05 ) . Conclusion The Human Immunoglobulin combined Platelet transfusion can regulate the body's immune function of the idioPathic thrombocytoPenic PurPura Patients, and imProve the Prognosis of the Patients.
